The Erectile Dysfunction Treatment Market is estimated to be valued at US$ 4.54 Bn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Erectile dysfunction treatment aims to reverse the problem by addressing its underlying physical causes or by using devices or medications to enable sexual activity. Oral treatments include phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). Other treatment options include penile injections, penile implants, or external penile devices. Advancements in treatment products have significantly enhanced sexual experiences and relationships of people suffering from erectile dysfunction.
Market key trends:
The growing geriatric population is expected to drive the demand for ED treatment. Erectile dysfunction is more common in older men and its prevalence increases with age. Over 40% of men experience ED by the age of 70. As life expectancy increases globally, the aging population is expected to fuel the demand. Further, rising awareness regarding sexual well-being and availability of effective treatment options are encouraging patients to openly seek treatment rather than internalizing the condition. Companies are introducing innovative treatment options such as topical gels, wearable devices, and therapies that provide significant enhancements over existing oral drug therapies. This is expected to revolutionize the erectile dysfunction treatment market during the forecast period.
Porter's Analysis:
Threat of new entrants: Low barriers to entry incentivizes new players given the lucrative market potential. However, existing players enjoy economies of scale and brand loyalty advantages.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of treatment alternatives and personalized nature of condition. Price sensitivity also varies significantly.
Bargaining power of suppliers: Suppliers of active pharmaceutical ingredients and key materials face moderate pressure given requirements around purity and manufacturing standards. Threat of forward integration also exists.
Threat of new substitutes: Alternatives aiming to enhance erectile function and related treatments emerging but branded drugs still hold major market share relying on clinical validity and reputation.
Competitive rivalry: Fierce competition exists among leading global pharmaceutical companies to develop innovative solutions and command larger market share. Pricing pressure and patent expirations also influence competition.
SWOT Analysis:
Strengths: Rising health awareness, growing geriatric population base, and social acceptance boosting demand. Established distribution networks and manufacturing infrastructure help maintain scale.
Weaknesses: High R&D investment requirements and stringent regulations delay new product approvals. Dependency on few drugs still under patent exposes revenues.
Opportunities: Emerging economies with increasing healthcare spends present massive untapped opportunities. Ongoing innovations to introduce convenient delivery options.
Threats: Expiry of patents on blockbuster drugs impacting revenues. Stringent price controls and reimbursement policies pose challenges. Side effects of medications and stigma around condition also restrict uptake.
Key Takeaways:
The Global Erectile Dysfunction Treatment Market Demand is expected to witness high growth, exhibiting CAGR of 7.6% over the forecast period, due to increasing health awareness and destigmatization of condition. By 2030, the erectile dysfunction treatment market size is estimated to reach US$ 9 Bn.
Regional analysis: North America currently dominates the erectile dysfunction treatment market owing to increasing diagnosed patient base and progressive medical reimbursement scenario facilitating higher treatment uptake. Europe follows aided by favorable government support for novel drug development. Asia Pacific is anticipated to witness fastest gains over the coming years on back of rising living standards, growing medical tourism, and expanding healthcare infrastructure in populous nations like China and India.
Key players operating in the erectile dysfunction treatment market are Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific, Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLC. These companies compete based on portfolio expansion, generic over-the-counter offerings, and geographical penetration into emerging Asia Pacific.
Read More:
https://www.newsanalyticspro.com/erectile-dysfunction-treatment-market-demand-insights-and-growth/
